Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome

M. R. Bishop, J. D. Jackson, S. R. Tarantolo, B. O'Kane-Murphy, P. L. Iversen, E. Bayever, Shantaram S Joshi, John G Sharp, J. L. Pierson, Phyllis Irene Warkentin, James Olen Armitage, A. Kessinger

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Effective ex vivo purging techniques can decrease the likelihood of infusing bone marrow contaminated with leukemic cells during autologous transplantation. In preliminary studies, OL(1)p53, a 20-mer phosphorothioate oligonucleotide directed against p53 mRNA, decreased the number of acute myelogenous leukemia (AML) cells in vitro, suggesting a possible role for OL(1)p53 in purging bone marrow harvests of leukemia cells. To demonstrate that OL(1)p53 was nontoxic to hematopoietic progenitor cells, normal bone marrow cells were incubated with 10 μM OL(1)p53 for 36 h, and hematopoietic progenitor cell survival was determined by in vitro colony assays. OL(1)p53 had no toxic effect on the growth of either myeloid (CFU-GM) or erythroid (BFU-E) progenitor cells. OL(1)p53 was then used to ex vivo purge bone marrow harvests from nine patients with either AML or myelodysplastic syndrome (MDS). Bone marrow cells were incubated-with 10 μM OL(1)p53 for 36 h before transplantation. The median times posttransplantation for the patient to recover an absolute neutrophil count greater than 0.5 × 109/L and a platelet transfusion independence were 30 days and 56 days, respectively. Incubation of bone marrow cells with OL(1)p53 had no detrimental effect on the growth of hematopoietic progenitor cells, and transplantation of autologous bone marrow cells treated with the phosphorothioate oligonucleotide, OL(1)p53, resulted in successful recovery of circulating neutrophils following high-dose therapy in patients with AML or MDS. The data show that OL(1)p53 can be used safely to purge autologous bone marrow harvests from patients with leukemia.

Original languageEnglish (US)
Pages (from-to)441-446
Number of pages6
JournalJournal of Hematotherapy and Stem Cell Research
Volume6
Issue number5
StatePublished - Oct 1 1997

Fingerprint

Phosphorothioate Oligonucleotides
Autologous Transplantation
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Bone Marrow
Bone Marrow Cells
Hematopoietic Stem Cells
Therapeutics
Leukemia
Bone Marrow Purging
Neutrophils
OL(1)p53
Platelet Transfusion
Granulocyte-Macrophage Progenitor Cells
Erythroid Precursor Cells
Poisons
Cell Transplantation
Growth
Cell Survival
Stem Cells

ASJC Scopus subject areas

  • Immunology
  • Hematology

Cite this

Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. / Bishop, M. R.; Jackson, J. D.; Tarantolo, S. R.; O'Kane-Murphy, B.; Iversen, P. L.; Bayever, E.; Joshi, Shantaram S; Sharp, John G; Pierson, J. L.; Warkentin, Phyllis Irene; Armitage, James Olen; Kessinger, A.

In: Journal of Hematotherapy and Stem Cell Research, Vol. 6, No. 5, 01.10.1997, p. 441-446.

Research output: Contribution to journalArticle

@article{673a08e8d0d64a6a8033f274f90f5011,
title = "Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome",
abstract = "Effective ex vivo purging techniques can decrease the likelihood of infusing bone marrow contaminated with leukemic cells during autologous transplantation. In preliminary studies, OL(1)p53, a 20-mer phosphorothioate oligonucleotide directed against p53 mRNA, decreased the number of acute myelogenous leukemia (AML) cells in vitro, suggesting a possible role for OL(1)p53 in purging bone marrow harvests of leukemia cells. To demonstrate that OL(1)p53 was nontoxic to hematopoietic progenitor cells, normal bone marrow cells were incubated with 10 μM OL(1)p53 for 36 h, and hematopoietic progenitor cell survival was determined by in vitro colony assays. OL(1)p53 had no toxic effect on the growth of either myeloid (CFU-GM) or erythroid (BFU-E) progenitor cells. OL(1)p53 was then used to ex vivo purge bone marrow harvests from nine patients with either AML or myelodysplastic syndrome (MDS). Bone marrow cells were incubated-with 10 μM OL(1)p53 for 36 h before transplantation. The median times posttransplantation for the patient to recover an absolute neutrophil count greater than 0.5 × 109/L and a platelet transfusion independence were 30 days and 56 days, respectively. Incubation of bone marrow cells with OL(1)p53 had no detrimental effect on the growth of hematopoietic progenitor cells, and transplantation of autologous bone marrow cells treated with the phosphorothioate oligonucleotide, OL(1)p53, resulted in successful recovery of circulating neutrophils following high-dose therapy in patients with AML or MDS. The data show that OL(1)p53 can be used safely to purge autologous bone marrow harvests from patients with leukemia.",
author = "Bishop, {M. R.} and Jackson, {J. D.} and Tarantolo, {S. R.} and B. O'Kane-Murphy and Iversen, {P. L.} and E. Bayever and Joshi, {Shantaram S} and Sharp, {John G} and Pierson, {J. L.} and Warkentin, {Phyllis Irene} and Armitage, {James Olen} and A. Kessinger",
year = "1997",
month = "10",
day = "1",
language = "English (US)",
volume = "6",
pages = "441--446",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome

AU - Bishop, M. R.

AU - Jackson, J. D.

AU - Tarantolo, S. R.

AU - O'Kane-Murphy, B.

AU - Iversen, P. L.

AU - Bayever, E.

AU - Joshi, Shantaram S

AU - Sharp, John G

AU - Pierson, J. L.

AU - Warkentin, Phyllis Irene

AU - Armitage, James Olen

AU - Kessinger, A.

PY - 1997/10/1

Y1 - 1997/10/1

N2 - Effective ex vivo purging techniques can decrease the likelihood of infusing bone marrow contaminated with leukemic cells during autologous transplantation. In preliminary studies, OL(1)p53, a 20-mer phosphorothioate oligonucleotide directed against p53 mRNA, decreased the number of acute myelogenous leukemia (AML) cells in vitro, suggesting a possible role for OL(1)p53 in purging bone marrow harvests of leukemia cells. To demonstrate that OL(1)p53 was nontoxic to hematopoietic progenitor cells, normal bone marrow cells were incubated with 10 μM OL(1)p53 for 36 h, and hematopoietic progenitor cell survival was determined by in vitro colony assays. OL(1)p53 had no toxic effect on the growth of either myeloid (CFU-GM) or erythroid (BFU-E) progenitor cells. OL(1)p53 was then used to ex vivo purge bone marrow harvests from nine patients with either AML or myelodysplastic syndrome (MDS). Bone marrow cells were incubated-with 10 μM OL(1)p53 for 36 h before transplantation. The median times posttransplantation for the patient to recover an absolute neutrophil count greater than 0.5 × 109/L and a platelet transfusion independence were 30 days and 56 days, respectively. Incubation of bone marrow cells with OL(1)p53 had no detrimental effect on the growth of hematopoietic progenitor cells, and transplantation of autologous bone marrow cells treated with the phosphorothioate oligonucleotide, OL(1)p53, resulted in successful recovery of circulating neutrophils following high-dose therapy in patients with AML or MDS. The data show that OL(1)p53 can be used safely to purge autologous bone marrow harvests from patients with leukemia.

AB - Effective ex vivo purging techniques can decrease the likelihood of infusing bone marrow contaminated with leukemic cells during autologous transplantation. In preliminary studies, OL(1)p53, a 20-mer phosphorothioate oligonucleotide directed against p53 mRNA, decreased the number of acute myelogenous leukemia (AML) cells in vitro, suggesting a possible role for OL(1)p53 in purging bone marrow harvests of leukemia cells. To demonstrate that OL(1)p53 was nontoxic to hematopoietic progenitor cells, normal bone marrow cells were incubated with 10 μM OL(1)p53 for 36 h, and hematopoietic progenitor cell survival was determined by in vitro colony assays. OL(1)p53 had no toxic effect on the growth of either myeloid (CFU-GM) or erythroid (BFU-E) progenitor cells. OL(1)p53 was then used to ex vivo purge bone marrow harvests from nine patients with either AML or myelodysplastic syndrome (MDS). Bone marrow cells were incubated-with 10 μM OL(1)p53 for 36 h before transplantation. The median times posttransplantation for the patient to recover an absolute neutrophil count greater than 0.5 × 109/L and a platelet transfusion independence were 30 days and 56 days, respectively. Incubation of bone marrow cells with OL(1)p53 had no detrimental effect on the growth of hematopoietic progenitor cells, and transplantation of autologous bone marrow cells treated with the phosphorothioate oligonucleotide, OL(1)p53, resulted in successful recovery of circulating neutrophils following high-dose therapy in patients with AML or MDS. The data show that OL(1)p53 can be used safely to purge autologous bone marrow harvests from patients with leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0030828589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030828589&partnerID=8YFLogxK

M3 - Article

C2 - 9368180

AN - SCOPUS:0030828589

VL - 6

SP - 441

EP - 446

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 5

ER -